Toll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function

Area of Science:

• Immunology
• Pharmacology

Background:

• Fcγ receptor (FcγR) activation on monocytes/macrophages drives phagocytosis and cytokine release for eliminating antibody-coated targets.
• Toll-like receptor 2 (TLR2) recognizes microbial components, inducing potent pro-inflammatory responses in immune cells.

Purpose of the Study:

• To investigate if TLR2 agonists can augment FcγR activity for enhanced antibody therapy.
• To explore the molecular mechanisms underlying TLR2-mediated FcγR modulation.

Main Methods:

• Human peripheral blood monocytes were treated with the TLR2 agonist Pam2CSK4.
• FcγR-mediated functions (cytokine production, phagocytosis) and receptor expression were analyzed.
• Molecular mechanisms involving FcγRIIa, FcγRIIb, and SHIP were investigated.
• A murine Her2/neu solid tumor model was used to assess the in vivo efficacy of Pam2CSK4 with anti-Her2 antibody therapy.

Main Results:

• Pam2CSK4 significantly enhanced FcγR-mediated cytokine production and phagocytic ability in monocytes.
• Molecular analysis revealed increased FcγRIIa and common γ subunit expression, alongside decreased SHIP expression, which counteracts FcγRIIb inhibition.
• Pam2CSK4 treatment significantly improved the efficacy of anti-Her2 antibody in reducing tumor growth in vivo.
• A related TLR2 agonist, Pam3CSK4, also demonstrated significant enhancement of FcγR function and expression.

Conclusions:

• TLR2 activation positively modulates FcγR function and expression.
• TLR2 agonists represent a potential adjuvant strategy to enhance the effectiveness of antitumor antibody therapies.